CureVac

A beneficial deal

31/08/24 -"We have integrated the recent figures, which were broadly in line with our expectations. The positive from the out-licencing of the most advanced pipeline assets (all the mRNA vaccine candidates ..."

PDF page sample
Pages
55
Language
English
Published on
31/08/24
Download
You may also be interested by these reports :
06/11/25
The Q3 results surpassed expectations, backed by strong performance from Oncology, Respiratory & Immunology, and Rare Disease medicines. Now, the ...
06/11/25
The Q3 profits were ahead of consensus and, consequently, the management upgraded its 2025 guidance at February 2025 FX rates. However, FX headwinds ...
05/11/25
The Q3 results missed expectations, as Novo contended with competition from compounding pharmacies and Eli Lilly. Moreover, the management again ...
04/11/25
The Q3 operating profitability exceeded expectations, though sales fell short of consensus. The management reaffirmed its full-year guidance. While ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO